ABSTRACT
Rationale and objectives Acute kidney injury (AKI) is common among hospitalized patients and has a significant impact on morbidity and mortality. While early prediction of AKI has the potential to reduce adverse patient outcomes, it remains a difficult condition to predict and diagnose. The purpose of this study was to evaluate the ability of a machine learning algorithm to predict for AKI KDIGO Stage 2 or 3 up to 72 hours in advance of onset using convolutional recurrent neural nets (CNN) and patient Electronic Health Record (EHR) data.
Methods A CNN prediction system was developed to continuously and automatically monitor for incipient AKI. 7122 patient encounters were retrospectively analyzed from the Medical Information Mart for Intensive Care III (MIMIC-III) database.
New Predictors and Established Predictors New predictor - CNN machine learning-based AKI prediction model. Established predictors - XGBoost AKI prediction model and the Sequential Organ Failure Assessment (SOFA) scoring system.
Outcomes AKI onset.
Analytical Approach The model was trained on routinely-collected patient EHR data. Measurements included Area Under the Receiver Operating Characteristic (AUROC) curve, positive predictive value (PPV), and a battery of additional performance metrics for 72 hour advance prediction of AKI onset.
Results On a hold-out test set, the algorithm attained an AUROC of 0.85 and PPV of 0.25, relative to a cohort AKI prevalence of 5.21%, for long-horizon AKI prediction at a 72-hour window prior to onset.
Conclusions A CNN machine learning-based AKI prediction model outperforms XGBoost and the SOFA scoring system, demonstrating superior performance in predicting acute kidney injury 72 hours prior to onset, without reliance on changes in serum creatinine.
Competing Interest Statement
All authors who have affiliations listed with Dascena (Oakland, California, USA) are employees or contractors of Dascena.
Funding Statement
This work was supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [grant ID: 1R43AA02767401]
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are publicly available from http://www.nature.com/articles/sdata201635.